- The fix-dose coformulation of Albendazole/Ivermectine is due to enter regulatory agencies
- Acceptability and safety studies are underway
- The access plan is being developed
- Investigadores principales de cada uno de los partners
- Ideas generales importantes
- Integration across programs (these results have implications beyond STH)
- Progress has been achieved through public-private partnerships but more partners are needed to reach the ultimate goal.
- El abstract del proyecto?
- ## Investigadores principales de cada uno de los partners
- ## Abstract del proyecto
- [[Soil-Transmitted Helminths]] (STH) remain a significant public health problem with recognized obstacles for control and elimination with the current benzimidazole regimens in [[Mass Drug Administration]] (MDA) campaigns. Renewed targets from [[WHO]] for 2030 include elimination of [[STH]] morbidity in pre-school and school age children (PSAC & SAC), increased country governance and financial support and a strongyloidiasis control program; 2030 has also been targeted by [[WHO]] for controlling NTDs to attain the Sustainable Development Goals.
The current proposal aims at accelerating the implementation of an innovative [[health]] technology, a [[Fixed-Dose Combination]] (FDC) tablet of co-formulated [[albendazole]] and ivermectin, with adequate safety and significantly superior efficacy against T. trichiura in a registrational randomized clinical trial. This trial is being conducted in Ethiopia, [[Kenya]] and Mozambique with the guidance of EMA and sponsored [[by]] [[EDCTP]] (STOP projects) with a Phase II trial completed and a Phase III currently recruiting.
Borja Robert
11 months ago